Targets › TSHR
2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2030.
Receptor for the thyroid-stimulating hormone (TSH) or thyrotropin. Also acts as a receptor for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or thyrostimulin. (UniProt, P16473)
Open in Phaseline: the race on TSHR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris | rhTSH stimulation (Thyrogen) Recombinant human thyroid-stimulating hormone (TSH receptor agonist) | TSHR | Phase 3 | Low Risk Differentiated Thyroid Cancer | Jan 2030 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Thyrogen Recombinant human TSH (rhTSH) to stimulate thyroid hormone production | TSHR | Phase 2 | Thyroid Cancer | Nov 2035 |
Low Risk Differentiated Thyroid Cancer (1) Thyroid Cancer (1)
small molecule (2)
Gustave Roussy, Cancer Campus, Grand Paris (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.